Search Results for "ATTRv"
Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.
More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.
For more information about our FDA-approved therapies, please see the Full Prescribing Information:
NfL as a Potential Biomarker in hATTR Amyloidosis
This slide deck presents an overview of neurofilament light chain (NfL) and data evaluating its use as a biomarker in hATTR amyloidosis, including data from the APOLLO, Global OLE, and HELIOS-A studies.
This slide deck presents an overview of neurofilament light chain (NfL) and data evaluating its use as a biomarker in hATTR amyloidosis, including data from the APOLLO, Global OLE, and HELIOS-A studies.
Insights from the HELIOS-A Study
This deck highlights data from the Phase 3 HELIOS-A trial of vutrisiran in patients with hATTR-PN.
This deck highlights data from the Phase 3 HELIOS-A trial of vutrisiran in patients with hATTR-PN.
Musculoskeletal Manifestations Associated with ATTR Amyloidosis
This slide deck provides disease education on ATTR amyloidosis, focusing on the musculoskeletal manifestations associated with the disease and their importance for early diagnosis and patient care.
This slide deck provides disease education on ATTR amyloidosis, focusing on the musculoskeletal manifestations associated with the disease and their importance for early diagnosis and patient care.
Vutrisiran Treatment in Patients with Transthyretin Amyloidosis with Cardiomyopathy
This asset represents the HELIOS-B primary results, published in the New England Journal of Medicine, in slide deck form.
This asset represents the HELIOS-B primary results, published in the New England Journal of Medicine, in slide deck form.
Vutrisiran: HELIOS-A Study
Standard response letter on vutrisiran and results from the HELIOS-A study evaluating efficacy and safety of vutrisiran in patients with the polyneuropathy of hATTR.
Standard response letter on vutrisiran and results from the HELIOS-A study evaluating efficacy and safety of vutrisiran in patients with the polyneuropathy of hATTR.
